[go: up one dir, main page]

MX2022003365A - Anticuerpos de un solo dominio dirigidos contra lilrb2. - Google Patents

Anticuerpos de un solo dominio dirigidos contra lilrb2.

Info

Publication number
MX2022003365A
MX2022003365A MX2022003365A MX2022003365A MX2022003365A MX 2022003365 A MX2022003365 A MX 2022003365A MX 2022003365 A MX2022003365 A MX 2022003365A MX 2022003365 A MX2022003365 A MX 2022003365A MX 2022003365 A MX2022003365 A MX 2022003365A
Authority
MX
Mexico
Prior art keywords
directed against
domain antibodies
antibodies directed
single domain
lilrb2
Prior art date
Application number
MX2022003365A
Other languages
English (en)
Inventor
Julien Caumartin
Maria Loustau
Lise Hunault
Pierre Langlade-Demoyen
Original Assignee
Invectys SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invectys SAS filed Critical Invectys SAS
Publication of MX2022003365A publication Critical patent/MX2022003365A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

La presente invención se refiere a anticuerpos de un solo dominio (sdAbs) dirigidos contra el miembro 2 de la subfamilia B del receptor de tipo inmunoglobulina leucocitaria (LILRB2), composiciones farmacéuticas que los comprenden y sus usos en diagnóstico y en terapia.
MX2022003365A 2019-09-20 2020-09-18 Anticuerpos de un solo dominio dirigidos contra lilrb2. MX2022003365A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19306148 2019-09-20
PCT/EP2020/076198 WO2021053199A1 (en) 2019-09-20 2020-09-18 Single-domain antibodies directed against lilrb2

Publications (1)

Publication Number Publication Date
MX2022003365A true MX2022003365A (es) 2022-08-22

Family

ID=68654426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003365A MX2022003365A (es) 2019-09-20 2020-09-18 Anticuerpos de un solo dominio dirigidos contra lilrb2.

Country Status (11)

Country Link
US (1) US20230235050A1 (es)
EP (1) EP4031572A1 (es)
JP (1) JP7627687B2 (es)
KR (1) KR20220128332A (es)
CN (1) CN115066435B (es)
AU (1) AU2020351274A1 (es)
BR (1) BR112022004534A2 (es)
CA (1) CA3154450A1 (es)
IL (1) IL291506A (es)
MX (1) MX2022003365A (es)
WO (1) WO2021053199A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805568B (zh) * 2022-06-28 2022-09-02 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
CN114805580B (zh) * 2022-06-28 2022-09-06 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
CN119604531A (zh) * 2022-07-29 2025-03-11 盛禾(中国)生物制药有限公司 一种抗ilt4的单域抗体及其应用
EP4577573A1 (en) * 2022-08-22 2025-07-02 Antengene Biologics Limited Novel anti-lilrb2 antibodies and uses thereof
WO2024108568A1 (zh) * 2022-11-25 2024-05-30 深圳先进技术研究院 抗人类白细胞抗原-g纳米抗体及其制备方法与应用
CN119176874A (zh) * 2023-06-21 2024-12-24 康源博创生物科技(北京)有限公司 一种能够结合lilrb2的抗体或其抗原结合片段
CN117169505A (zh) * 2023-09-05 2023-12-05 中日友好医院(中日友好临床医学研究所) 一种结直肠癌治疗靶点和血清标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
AU2008252854A1 (en) * 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
CN107530402B (zh) 2015-03-06 2021-06-11 德克萨斯大学体系董事会 抗lilrb抗体及其在检测和治疗癌症中的用途
JP7391868B2 (ja) 2017-12-22 2023-12-05 ジョウンセ セラピューティクス， インク． Ｌｉｌｒｂ２に対する抗体
US20210122819A1 (en) * 2018-01-18 2021-04-29 Adanate, Inc. Anti-lilrb antibodies and uses thereof

Also Published As

Publication number Publication date
CN115066435B (zh) 2025-05-02
JP7627687B2 (ja) 2025-02-06
BR112022004534A2 (pt) 2022-06-07
EP4031572A1 (en) 2022-07-27
US20230235050A1 (en) 2023-07-27
JP2022548764A (ja) 2022-11-21
AU2020351274A1 (en) 2022-05-05
CN115066435A (zh) 2022-09-16
CA3154450A1 (en) 2021-03-25
WO2021053199A1 (en) 2021-03-25
KR20220128332A (ko) 2022-09-20
IL291506A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
MX2022003365A (es) Anticuerpos de un solo dominio dirigidos contra lilrb2.
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2020009051A (es) Receptores de citocina quimericos inducibles.
MA50949B1 (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MX2025000940A (es) Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
MA38248A1 (fr) Compositions pesticides et procédés associés
CY1115919T1 (el) Ενωσεις ενεργοποιησης τελομερασης και μεθοδοι χρησης αυτων
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
JOP20170017B1 (ar) تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
EA201170227A1 (ru) Имидазолкарбоксамиды
WO2018098117A8 (en) SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EA201900562A1 (ru) Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты
EP4245775A3 (en) Multi-specific binding conjugate, related pharmaceutical compositions and use
CY1125348T1 (el) Νεοι ανταγωνιστες υποδοχεων β2 βραδυκινινης
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
AU2018337947A1 (en) Compositions and methods for predicting response to NaPi2b-targeted therapy
JOP20210011A1 (ar) مستقبلات خيمرية لـ steap1 وطرق استخدامها
MX2020007731A (es) Compuestos moduladores de receptor de estrogeno.
AU2018279184A1 (en) Anti-TrkB antibodies
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
MX2022007960A (es) Nuevos anticuerpos anti-fgfr2b.
MY206042A (en) Novel compositions for bitterants